Incidence of Vasospasm, Outcome, and Quality of Life after Endovascular and Surgical Treatment of Ruptured Intracranial Aneurysms: Results of a Single-Center Prospective Study in Switzerland
Table 3
Risk factors for cerebral vasospasm on admission and during the treatment in patients undergoing surgical and endovascular treatment.
Surgical treatment
value surgical versus
Endovascular treatment
Total
Clinical CVS
No clinical CVS
endovascular
Total
Clinical CVS
no clinical CVS
Total patients
41
12
29
—
25
6
19
Patients with angiographic CVS (%)
70.7
91.7
62.1
NS
52
83.3
36.8
Patient with clinical CVS (%)
29.2
—
—
NS
24
—
—
Platelet count (×1000/μL)
NS
Lowest platelet count/admission count > 0.7 (%)
85.4
83
86
—
80
66
84
Hematocrit (L/L)
Mean systolic blood pressure (mmHg)
NS
Episodes of hypotension (SBP <105 mmHg)
NS
Maximal ICP (mmHg)*
NS
Patients undergoing ICP monitoring (%)
31.7
42
27
—
48
66
42
Angiographic vasospasm on admission (%)
7.3
8.3
6.9
—
16
50
5.3
Fisher CT grading
NS
Grade 1-2 (%)
17.1
8.3
20.7
—
16
16.7
15.8
Grade 3-4 (%)
82.9
91.7
79.3
—
86
83.3
84.2
Mean fluid balance (mL)
NS
Patients with negative fluid balance (%)
63.4
75
58.7
—
60
83.3
52.6
Episodes of negative fluid balance
NS
Inclusion in the Clazosentan study* ()
23
7 (28.1%)
16 (69.5%)
NS
9
2 (22.2%)
7 (77.7%)
Sodium (mmol/L)
Glucose (mmol/L)
NS
Cigarette use (%)
48.8
75
38
—
52
33.3
57.9
Cigarette use (py)
NS
CVS: cerebral vasospasm; ICP: intracranial pressure; SBP: systolic blood pressure; NS: no statistically significant; *: including all patients receiving placebo and clazosentan (1, 5, and 15 mg). All data are expressed as mean ± standard deviation.